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Bullous pemphigoid (BP) can be associated with various co-morbidities such as 
neurological disorders, hypertension or diabetes (Pankakoski, 2018).  Organ-specific or non-
organ specific autoimmune comorbidities have been also reported (Ljubojevic, 2012). They 
may have implication during the management of the patient. We report the fortuitous 
discovery of autoimmune atrophic chronic gastritis during the management of BP by 
methotrexate. To date, atrophic gastritis/pernicious anemia has been reported on two 
previous occasion (Obasi, 1977; Callen, 1978). 
An otherwise healthy 72-year-old man was diagnosed with typical BP that 
evolved for a month.  He had generalized tense blisters with pseudo-urticarial and 
eczematous lesions, linear deposits of IgG and C3 along the basement membrane zone on 
direct immunofluorescence and elevated circulating BP180 antibodies (140 U/mL, N<9). 
Clobetasol proprionate ointment daily was initiated with oral methotrexate (MTX, 10 mg the 
first week and then 15 mg weekly) and oral folic acid supplementation 5 mg the following 
day. At initiation mean corpuscular volume (MCV) was slightly elevated (102 fl) with low 
erythrocytes count (3.93 x 109, N> 4.25) without anemia. White blood count, creatinine, 
glomerular filtration rate, albumin level and liver enzymes were within normal ranges.  At 
one-month follow-up, patient had considerably improved without any new blisters. At four-
month follow-up, BP was in remission. MCV had meanwhile increased progressively up to 
107 fl. Serum folate was within normal range while serum B12 levels were undetectable (< 5 
pmol/L, N>35). B12 deficiency was confirmed on a second sample. Parietal cell antibodies 
were positive 45 U/mL (N<7), while intrinsic factor antibodies negative 1.08 AU/mL 
(N>1.53). Patient was supplemented by oral cyanocobalamin 1 mg/day. After three months 
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of oral supplementation, MCV and erythrocyte count were within normal range. Biopsies of 
the corpus mucosa during gastroscopy confirmed chronic atrophic gastritis without ulcer or 
cancer. Helicobacter pylori was absent. The daily supplement of 1 mg cyanocobalamine was 
not associated with any loss of MTX efficacy against BP.  
We report here a case of atrophic gastritis associated with BP. Chronic gastritis 
is quite frequent in Nordic countries (Sipponen, 2015). It is usually associated with H. pylori 
infection in 90% of the cases. The rest of the cases can be of auto-immune origin with auto-
antibodies against parietal cells and/or intrinsic factor (Sipponen, 2015). To the best of our 
knowledge two previous patients, both women aged 74 and 70 years, were diagnosed with 
pernicious anemia (PA). In the first case, a 74-year-old woman had had PA from 29 years 
before BP onset. In the second case, it was a fortuitous finding at the time of BP diagnosis in 
a 70-year-old woman. The association of both conditions may be of course fortuitous or 
under-reported as chronic gastritis is a frequent finding. Mechanisms underlying a possible 
link include: cross-reactivity of autoantibodies between tissues, epitope spreading, or 
linkage to human leukocytes antigen alleles (Narla, 2020). In a national inpatient sample of 
US hospitalizations, Narla et al. found that BP was associated with an elevated number of 
autoimmune diseases, vitiligo and chronic urticaria especially (Narla, 2020). BP was also 
found to be associated with PA, but the association was not significant after adjustment in 
multivariable models. 
As MTX is a common treatment in BP (Feliciani, 2015), this differential 
diagnosis should be kept in mind in case of unexplained increase of MCV during treatment 
of patients with BP.   
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